Sanofi said it is investing €300 million to expand its site in Geel, Belgium, to drive the future of biologics by expanding manufacturing and commercial capabilities in order to ensure quality, capacity, and scale. Through the investment, Sanofi plans to adapt and expand existing production capabilities to support Sanofi’s pipeline of monoclonal antibodies. Updates to the existing facility will include the development of new laboratories focused on quality control and manufacturing scie...